Board of Directors
Partners & Advisors
6 August 2021
Le Temps is reporting about CHF 7.2 million of seed funding raised for the development of RocketVax’s SARS-CoV-2 vaccine
“Founded in 2020, Basel-based company RocketVax has just secured funding to launch the pre-clinical phase of its Covid-19 vaccine development”.
SHARE THIS NEWS